• Capecitabine: Mechanism, Selectivity, and Oncology Benchmark

  2026-07-22

  Capecitabine, a fluoropyrimidine prodrug, delivers tumor-selective 5-FU via enzymatic activation in cancer tissues. Its efficacy in preclinical oncology models stems from its targeted apoptosis induction and favorable solubility profile. This article details its biochemical rationale, evidence, and integration into advanced tumor microenvironment workflows.

• Photothermal Therapy Enhances CD47 Blockade in OSCC Immunoth

  2026-07-21

  The reference study demonstrates that photothermal therapy (PTT), when combined with CD47 immune checkpoint blockade, synergistically boosts anti-tumor macrophage responses in oral squamous cell carcinoma (OSCC). By inducing calreticulin exposure and remodeling the extracellular matrix, this combination addresses two major barriers to effective macrophage-mediated tumor clearance.

• Isoprinosine for Viral Immunotherapy: Applied Workflows & In

  2026-07-21

  Isoprinosine (inosine pranobex) stands out as an immunomodulatory agent that not only inhibits viral replication but also enhances host immune responses. This article delivers actionable protocols, troubleshooting tips, and advanced applications—bridging mechanistic insights from herpesvirus research to practical antiviral assay optimization.

• PDHA1 Succinylation Drives Immune Escape in Cholangiocarcino

  2026-07-20

  A recent study demonstrates that PDHA1 succinylation at lysine 83 in cholangiocarcinoma promotes immune evasion by suppressing macrophage antigen presentation via α-ketoglutaric acid accumulation. Inhibiting this modification with CPI-613 restores immune sensitivity and enhances chemotherapy efficacy, providing a new angle for overcoming resistance in this cancer.

• Perospirone (SM-9018 Freebase): Applied Neurovascular Resear

  2026-07-20

  Perospirone (SM-9018 freebase) empowers translational studies at the intersection of neuropsychiatric and cardiovascular research, uniquely enabling concurrent modeling of serotonergic, dopaminergic, and vascular ion channel mechanisms. This guide delivers protocol-ready workflows, troubleshooting strategies, and practical insights for maximizing reproducibility and specificity in complex disease models.

• Isoprinosine and CLCC1: Next-Gen Strategies for Viral Egress

  2026-07-19

  Explore how Isoprinosine (inosine pranobex) redefines antiviral immunotherapy by targeting viral egress mechanisms, including CLCC1-mediated pathways. Gain practical insights on advanced applications and protocol optimization for acute respiratory and herpesvirus infections.

• Masitinib (AB1010): Technical Use in KIT/PDGFR Research Work

  2026-07-18

  Masitinib (AB1010) is a selective tyrosine kinase inhibitor for precise inhibition of KIT, PDGFRα, and PDGFRβ in cancer, mastocytosis, and inflammatory disease research. It should be used exclusively in DMSO-based protocols requiring high specificity and is not suitable for workflows needing aqueous or ethanol solubility or broad kinase inhibition.

• Precision Apoptosis Modulation: Caspase-3/7 Inhibition in Tr

  2026-07-17

  Explore how Caspase-3/7 Inhibitor I enables unprecedented precision in dissecting and modulating apoptosis pathways—bridging mechanistic cell death insights with strategic guidance for translational and veterinary researchers. With reference to recent advances in pathogen-induced apoptosis models and rigorous benchmarking in cancer and immune cell lines, this article provides a thought-leadership roadmap for leveraging selective caspase inhibition to drive hypothesis-driven discovery, robust assay design, and the next wave of therapeutic innovation.

• Phosphotungstic Acid Negative Stain Solution: Precision EM U

  2026-07-17

  Phosphotungstic Acid Negative Stain Solution (2%) empowers researchers to achieve high-contrast, reproducible electron microscopy for viruses, macromolecules, and glycans. Explore advanced workflows, troubleshooting, and protocol enhancements informed by cross-domain breakthroughs in glycan-targeted virology.

• Everolimus (RAD001): Decoding mTOR-Driven Proliferation and

  2026-07-16

  Explore how Everolimus (RAD001) uniquely modulates cancer cell proliferation and apoptosis by targeting mTOR, with a focus on nuanced assay design and data interpretation. This article uniquely integrates mechanistic insight with practical guidance for research applications.

• Perospirone Inhibits Vascular Kv1.5 Channels: Cardiovascular

  2026-07-16

  This study reveals that perospirone, an atypical antipsychotic, directly inhibits vascular Kv1.5 potassium channels in coronary arterial smooth muscle cells—a mechanism distinct from its canonical serotonergic and dopaminergic actions. These findings expand the mechanistic landscape of perospirone, underscoring its implications for both neuropsychiatric and cardiovascular research models.

• Monomethyl Auristatin E: Precision ADC Payload for Cancer Re

  2026-07-15

  Monomethyl auristatin E (MMAE) sets the standard for targeted cytotoxicity in antibody-drug conjugates (ADCs), enabling researchers to model therapy-resistant tumor biology and exploit vulnerabilities in cell division. This guide translates cutting-edge evidence and workflow optimizations into actionable strategies, ensuring reliable MMAE application across advanced cancer models.

• Losmapimod (GW856553X): Applied Workflows for Inflammation R

  2026-07-15

  Losmapimod (GW856553X) stands out as a dual-action, orally active p38 MAPK inhibitor enabling precise inflammation signaling modulation and vascular function studies. This guide details experimental protocols, troubleshooting strategies, and advanced applications, empowering researchers to achieve reproducible, high-impact results using APExBIO’s trusted reagent.

• In Vitro Metrics for Drug Response: Implications for Tyrosin

  2026-07-14

  Schwartz’s dissertation advances in vitro assessment of anticancer drug responses by distinguishing growth inhibition from cell death, demonstrating these are distinct yet often conflated phenomena. This nuanced approach has practical implications for designing and interpreting assays with targeted agents such as Tivozanib (AV-951), especially in anti-angiogenic and RCC research.

• Non-Canonical Dlat-Trpv3 Pathway Drives Adipose Thermogenesi

  2026-07-14

  This study uncovers a novel mechanism by which hyperforin promotes adipose thermogenesis via the Dlat-Trpv3-AMPK axis, offering a promising anti-obesity approach that avoids cardiovascular side effects of classical pathways. The findings offer new directions for metabolic disease research and highlight the value of targeting non-adrenergic signaling in adipocyte biology.

8421 records 5/562 page Previous Next 12345 下5页 Last page